Clinical Trial Update: Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a combination of Rituximab, Bortezomib, Bendamustine, and Dexamethasone in patients with Mantle cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Rituxan (rituximab)
• Treanda (Bendamustine)
• Velcade (bortezomib)

Snippet

Sponsor: French Innovative Leukemia Organisation | Conditions: Lymphoma | Phase 2 | Status: COMPLETED